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With the rapid development and popularization of laparoscopic and robotic radical 
gastrectomy, gastric cancer (GC) surgery has gradually entered a new era of precise 
minimally invasive surgery. The era of precision medicine has put forth new requirements 
for minimally invasive surgical treatment of patients with GC at different disease stages. 
For patients with early GC, avoiding surgical trauma caused by excessive lymph node 
(LN) dissection improves quality of life while pursuing radical treatment of the tumor. 
In patients with advanced GC, systematic LN dissection can be achieved without 
increasing surgical complications. With the successful application of indocyanine green 
(ICG) fluorescence imaging technology in minimally invasive surgical instrumentation 
in recent years, researchers have found that ICG fluorescence imaging yields good 
tissue penetration and can identify LNs in fat tissue better than other dyes. Therefore, 
whether ICG fluorescence imaging technology can guide surgeons in performing safe 
and effective LN dissection has attracted much attention. The present review discusses 
the clinical applications and research progress of ICG tracer-guided LN dissection in 
patients with GC.
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Background
Gastric cancer (GC) is the sixth most frequent 
malignancy and ranks third among tumor-related 
mortality worldwide [1]. Curative treatment of GC 
depends on operation-centered, comprehensive 
treatment. Simultaneously, complete resection of the 
tumor and radical lymphadenectomy are key points 
of the operation. Since Kitano et al. [2] first described 
laparoscopic distal gastrectomy in Japan in 1994, after 
more than 20 years of development[3,4], minimally 
invasive gastrectomy has been widely implemented in 
clinical practice. With advances in minimally invasive 
instrumentation and the development of minimally 
invasive technology in recent years, minimally invasive 
GC surgery has gradually entered the era of precision 
medicine. Therefore, accurate definition of the scope of 
lymph node (LN) dissection in early GC and ensuring the 
thoroughness of LN dissection in patients with advanced 
GC have become the focus of discussion in the field of 
minimally invasive gastrectomy. Individualized radical 
lymphadenectomy is becoming the goal of every surgeon 
performing minimally invasive procedures. Over the 
past several years, the emergence of indocyanine green 
(ICG) near-infrared (NIR) fluorescence imaging has 
provided a more feasible solution to the above problems 
[5-7].
Principle of ICG Fluorescence imaging technology
ICG is the only NIR contrast agent approved for a small 
number of surgical indications by the Food and Drug 
Administration and European Medicines Agency[8]. 
ICG is excited by external light at a wavelength range 
of 750–810 nm and emits NIR light at a wavelength of 
approximately 840 nm [9]. ICG injected locally around 
GC is absorbed by the lymphatic system and binds to 
albumin, eventually returning to the blood system 
with drainage of the lymphatic system. Due to the slow 
transport of the lymphatic system, ICG can persist for 
prolonged periods [10]. ICG fluorescence imaging 
technology is based on the above principles using 
special imaging equipment to track drainage of the 
lymphatic vessels and LNs. Because the rate of uptake 
of ICG varies among different tissues, it can effectively 
distinguish lymphoid tissue from perigastric vessels, fat, 
pancreas, and other tissues during surgery.
Development of ICG fluorescence imaging technology
As early as the beginning of the 21st century, Hiratsuka 
et al. [11] reported, for the first time, the application of 
an ICG LN tracing technique in sentinel LN biopsy for 
early GC in open surgery. Initially, sentinel LNs were 
identified only by the naked eye to determine whether 
they were stained by ICG. With the development 
of fluorescence imaging equipment, some centers 
have performed related studies investigating ICG 
fluorescence imaging of sentinel LN biopsy in open 
GC surgery [12,13]. However, due to the subjectivity of 
naked eye discrimination and the need for additional 
imaging equipment, it remains difficult to popularize 
ICG fluorescence imaging technology in open GC 
surgery. After 2010, with the successful integration of 
ICG fluorescence imaging technology in laparoscopic 
and robotic equipment [14], researchers have found 
that ICG fluorescence imaging provides better tissue 
penetration and signal stability than other dyes (such 
as 99m technetium-labeled tin colloid and isosulfan 
blue dye, among others) [6,7]. Therefore, based on the 
unique high-definition camera display system and clear 
magnification effect of minimally invasive equipment, 
ICG fluorescence imaging-guided sentinel LN biopsy 
and LN dissection has the characteristics of in vivo and 
real-time imaging. Perigastric LNs can be observed in 
a closer and more physiological condition, LNs can be 
mapped more accurately, and lymphadenectomy can 
be performed in real time (Figure 1). Minimally invasive 
radical gastrectomy guided by ICG fluorescence imaging 
has become a new area of exploration. To further 
standardize applications of ICG fluorescence imaging 
technology in the field of minimally invasive GC surgery, 
our center performed the first prospective, randomized, 
controlled study (FUGES-012) of ICG tracer-guided LN 
dissection during laparoscopic radical gastrectomy in 
patients with GC [15] from November 2018 to July 2019. 
That study aimed to promote the standardization of 
NIR imaging in the laparoscopic resection of GC and to 
establish a reference for the application of fluorescence 
imaging in the radical resection of digestive tract cancers. 
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Figure 1: 
Indocyanine green (ICG) tracer-guided lymph node (LN) 
dissection. 
A. Natural light mode. 
B. Near-infrared mode. 
C. Green fluorescence mode.
Application of ICG tracer-guided LN dissection in 
early GC
Traditionally, the treatment of early GC was based 
primarily on standard open gastrectomy and LN 
dissection. Due to the low rate of LN metastasis in 
early GC (0–10.6%) [16,17], advances in surgical 
instrumentation and surgical concepts, endoscopic 
treatment, rescue surgery after failure of endoscopic 
treatment, and minimally invasive radical surgery, 
represented by laparoscopic and robotic gastrectomy, 
have become the main theme of early GC treatment 
[13]. Some investigators have proposed that sentinel 
LN navigation surgery is an “accurate operation” 
under the guarantee of radical surgery based on the 
distribution and biopsy of sentinel LNs. Only metastatic 
LNs are dissected to avoid excessive LN dissection, 
reduce complications, preserve function, and improve 
quality of life in patients with early GC. However, 
due to the complexity of gastric lymphatic reflux 
and the jumping metastasis of GC, the application 
of sentinel LN navigation surgery in the field of GC 
remains controversial [18]. Among them, in addition 
to defining indications for sentinel LN dissection, 
accurate identification of sentinel LNs is also the focus of 
surgeons. In recent years, several studies [14,19,20] have 
confirmed that ICG is safe and feasible for mapping 
sentinel LNs in GC surgery, and that ICG fluorescence 
imaging technology has the advantages of intuitiveness, 
high sensitivity, and signal stability, which have 
gradually replaced the previous radiolabeled tin colloid 
and blue dye. Based on a previous report by Hiratsuka 
et al. [11], Japanese surgeons immediately performed 
the Japan Clinical Oncology Group multicenter trial 
JCOG0302 [21]. However, that trial was suspended due 
to its high false-negative rate. It should be noted that 
ICG was subserous injected in open surgery, without 
using fluorescence imaging, and the histopathological 
diagnosis rate was not high. Shoji et al [18] combined 
ICG submucosal injection with sentinel LN navigation 
biopsy in laparoscopic radical resection for early GC, 
and improved the method of intraoperative sentinel 
LN biopsy using a one-step nucleic acid amplification 
assay that can identify the expression of epithelial 
protein CK19 within 30 minutes. This compensates for 
shortcomings of low sensitivity and the time-consuming 
process of hematoxylin and eosin staining of frozen 
biopsy samples, and significantly reduces the false-
negative rate. We believe that with the development of 
imaging technology, drug administration regimens, and 
detection technology, the application of ICG fluorescence 
imaging technology in sentinel LN biopsy and function-
preserving surgery for early GC can be more secure.
 Although endoscopic resection can result in 
a radical effect in some early GCs, approximately 10% 
of patients experience LN metastasis after endoscopic 
resection [22]. Therefore, according to the condition 
of postoperatively resected specimens, some patients 
still need to undergo further rescue LN dissection. 
Recently, Roh et al. [23] reported that ICG fluorescence 
lymphography successfully visualized all draining LNs 
after endoscopic treatment, with very high sensitivity 
and negative predictive value for detecting metastatic 
LNs. Therefore, ICG fluorescence-guided LN dissection 
could be an alternative to systematic lymphadenectomy 
during additional surgery after endoscopic treatment.
 For early GC, minimally invasive radical 
gastrectomy, including laparoscopic and robotic D1 
+ or D2 radical gastrectomy, has become one of the 
main recommended treatments [16,24]. In terms of LN 
navigation in early GC, Tae-Han Kim et al. [25] reported 
that, among 43 cases of laparoscopic radical resection for 
early GC, the application of ICG increased the detection 
rate of LNs, especially in the infrapyloric region. In a 
prospective, single-arm study, Kwon et al. [26] reported 
that ICG tracing increased the number of LNs retrieved 
in patients with early GC and achieved complete LN 
dissection compared with a historical control group .
Application of ICG tracer-guided LN dissection in 
advanced GC Application of ICG tracer-guided LN 
dissection in advanced GC
Previous studies have shown that within the prescribed 
range of dissection, the more LNs dissected, the better 
the long-term survival of patients with GC [27-30]. 
Increasing the number of LN dissections and the number 
of positive LNs retrieved were highly significant to 
accurate patient staging and the choice of adjuvant 
treatment. Therefore, for advanced GC, it is important 
to thoroughly and effectively dissect perigastric LNs 
during surgery. In principle, D2 lymphadenectomy is 
indicated for advanced GC[16]. Presently, however, 
LN dissection is often performed under the naked 
eye according to the surgeon’s experience. Due to the 
complex anatomy of the perigastric vessels and fascia, 
the complicated characteristics of laparoscopic and 
robotic instrument operation, especially in patients 
with high body mass index, how to harvest a sufficient 
number of LNs efficiently and accurately without 
increasing complications remains a significant challenge 
for surgeons, especially for those newly trained. 
Because ICG can emit NIR light at a wavelength of 
840 nm after being excited, the penetration depth of 
the enhanced fluorescence is between 0.5 cm and 1 cm 
[31]. High-resolution signals are collected using high-
definition laparoscopy, and the outline and boundaries 
of perigastric LNs can be displayed clearly in real-time 
under fluorescence imaging, which helps guide surgeons 
in performing LN dissection within the prescribed range 
more confidently, calmly, and accurately. However, 
previous studies remain controversial as to whether 
ICG fluorescence imaging can increase the number of 
LNs dissected during minimally invasive GC surgery. 
Cianchi et al. [32] reported that the application of ICG 
tracer-guided LN dissection in robotic gastrectomy 
has similar short-term efficacy and postoperative 
complication rate as traditional robotic surgery and can 
harvest more LNs. However, Lan et al. [33] found that, 
compared with the non-ICG group, the ICG group did 
not increase the total number of dissected LNs. These 
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inconsistent results, however, may be explained by the 
selection bias inherent in retrospective investigations and 
the different inclusion/exclusion criteria and varying 
injection methods, time, and concentration(s) of ICG 
used across studies. Therefore, in addition to adopting 
strict prospective randomized controlled methods to 
select patients and ensure that the basic characteristics 
of patients were comparable, for the standardized use 
of ICG, the FUGES-012 study adopted unified and strict 
standards for preoperative injection, intraoperative 
photography and postoperative LN sorting, and 
recorded them by video or photographs. Through 
previous exploration, we found that, compared with 
intraoperative subserous injection of ICG, preoperative 
endoscopic submucosal injection is easier to control and 
saves time, and it is not easy to cause intraoperative 
leakage to the operative field or mistakenly inject 
vessels during the operation. In the FUGES-012 study, 
a modified intention-to-treat analysis included 258 
patients with clinical T1-4a GC (ICG group, n = 129; 
non-ICG group n = 129). The results showed that the 
average number of total LN dissections in the ICG group 
was significantly higher than that in the non-ICG group 
(50.5 vs. 42.0; P < 0.001). The postoperative recovery 
process and the 30-day incidence of complications were 
similar between the two groups. Further hierarchical 
analysis revealed that regardless of whether distal or 
total gastrectomy was performed, the average number 
of total LN dissections in ICG group was significantly 
higher than that in non-ICG group (distal gastrectomy, 
49.2 vs. 39.8; total gastrectomy, 52.1 vs. 43.1; P < 0.001). 
The results were published in JAMA Surgery [15]. 
At the same time, JAMA Surgery commissioned an 
invited commentary by Professor Marco G. Patti from 
the University of North Carolina (Capel Hill, NC, USA) 
[34]. He commented that the study was important for 
surgeons in Western countries and suggested that ICG 
should be routinely performed in GC surgery due to its 
simplicity and effectiveness.
Laparoscopic or robotic radical resection of GC has 
been widely performed all over the world owing to its 
minimally invasive advantages. However due to the 
difficulty of laparoscopic or robotic D2 LN dissection, 
performing minimally invasive D2 LN dissection in a 
standardized and efficient manner has become focus 
of attention for many surgeons. To objectively evaluate 
the quality of D2 LN dissection, Japanese investigators 
have proposed the concept of “LN noncompliance” [35]. 
Several studies have considered the LN noncompliance 
rate as a quality control index of D2 radical surgery for 
GC [36-39]. Even when standard D2 radical resection 
is performed, the LN noncompliance reported in the 
literature still fluctuates between 43.2% and 81.6%. 
Several previous clinical trials also reported a high LN 
noncompliance rate. The LN noncompliance rate of D2 
LN dissection in a Dutch trial[36] was as high as 81.6%. 
The D2 LN noncompliance rate in the COACT1001 
study from Korea was 47% in the laparoscopic distal 
gastrectomy group and 43.2% in the open distal 
gastrectomy group [37]. The LN noncompliance rate of 
D2 LNs in the CRITICS study was 58.9%[38]. A previous 
retrospective study performed at our center [40] revealed 
that the LN noncompliance rate in the laparoscopic 
distal gastrectomy group was 50.9% and 59.8% in the 
laparoscopic total gastrectomy group . In the FUGES-012 
study, through ICG tracing, the LN noncompliance rate in 
patients who underwent laparoscopic distal gastrectomy 
and those underwent laparoscopic total gastrectomy in 
the ICG group was 23.9% and 41.4%, respectively, which 
was significantly lower than that reported in previous 
studies. Therefore, the application of ICG tracer-guided 
LN dissection in laparoscopic radical resection of GC 
will help to reduce LN noncompliance. For advanced 
GC, it is recommended that ICG fluorescence imaging 
be routinely performed to guide laparoscopic or robotic 
radical GC surgery, and to guide the surgeon to harvest 
more LNs and improve the LN noncompliance rate.
Limitations and prospects
Due to the lack of survival data, whether ICG fluorescence 
imaging-guided LN dissection in minimally invasive GC 
surgery can improve the long-term prognosis of patients 
with GC still needs to be confirmed in multicenter, long-
term, follow-up studies. There are still some limitations 
to the application of ICG fluorescence-imaging-guided 
LN dissection. First, when ICG imaging indicates LNs 
beyond the scope of LN dissection (such as no.13, 14v, 
or 16a) in patients undergoing D1 + or D2 LN dissection, 
it is unclear whether the surgeon needs to dissect the 
fluorescent LNs. In the FUGES-012 study, No.14v LN 
exhibited fluorescence during the operation and was 
dissected and submitted for pathological examination. 
Interestingly, the rate of LN metastasis in patients with 
fluorescent No.14v was as high as 33.3%, which was 
significantly higher than reported in previous studies 
[41,42]. To clarify, it is suggested that future studies 
investigate guiding controversial No.14v dissection 
through ICG imaging. Second, the LN indicated by 
ICG fluorescence only shows that the LN receives 
lymphatic reflux from the tissue around the tumor and 
cannot accurately identify metastatic LNs. The accuracy 
reported in the literature is approximately 62.2–97.2%. 
At the same time, some false-negative rates have been 
reported, in which fluorescence was absent in the LN; 
however, postoperative pathological examination 
revealed the presence of metastasis, the incidence 
of which was 46.4–60.0% [13,21,32]. This inaccuracy 
may have been due to large-scale cancer invasion of 
lymphatic vessels or LNs blocked by cancer cells. In this 
case, ICG fluorescence was not detected in the metastatic 
LNs [43]. We believe that through rigorous development 
of clinical practices and technological innovations, the 
accuracy of this technology will improve. For example, 
ICG can be combined with targeting marker molecules, 
which can successfully identify metastatic cancer cells 
and specifically identify metastatic LNs. We look forward 
to further exploring indications for ICG fluorescence 
imaging that can accurately indicate metastatic LNs 
through prospective multicenter studies in the future.
Conclusions
In conclusion, ICG fluorescence imaging is an emerging 
new method in the era of precision treatment in 
minimally invasive surgery, and provides a more stable 
signal, more obvious background contrast, and deeper 
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penetration depth than other contrast agents. This 
technology is recommended as an effective method for 
sentinel LN mapping and LN dissection navigation in 
minimally invasive surgery for GC. The application of 
ICG tracer-guided LN dissection is helpful in completing 
D1+ or D2 LN dissection in laparoscopic and robotic 
radical gastrectomy, and to perform more precise LN 
dissection in function-preserving surgery. Novices of 
minimally invasive radical gastrectomy and experienced 
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